Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab...

Dr Zev Wainberg - University of California Los Angeles, California, USA

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer ( Dr Zev Wainberg - University of California Los Angeles, California, USA )

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C...

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )

FGFR as a tumour agnostic indicator and its importance in the diagnosis and...

Dr Christophe Massard and Prof Eva Compérat

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types ( Dr Christophe Massard and Prof Eva Compérat )

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory...

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA

$COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )$

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and...

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non...

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

$Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )$

Latest updates in exon 20 insertions focusing on targeted therapies, novel...

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

Efficacy and safety of tisagenlecleucel in adult patients with relapsed...

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA

$Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )$

More from ecancer